[HTML][HTML] Characteristics of real-world commercially insured patients with treatment-resistant depression initiated on esketamine nasal spray or conventional therapies …
Purpose This study aimed to characterize patients with treatment-resistant depression (TRD)
initiating esketamine or conventional therapies. Methods Adults with major depressive
disorder (MDD) were selected from the IBM MarketScan Databases. A claims-based
algorithm identified patients with evidence of TRD, defined as initiation of a new
antidepressant therapy after 2 different antidepressant trials of adequate dose and duration
during the most recent major depressive episode. Patients receiving treatment on/after …
initiating esketamine or conventional therapies. Methods Adults with major depressive
disorder (MDD) were selected from the IBM MarketScan Databases. A claims-based
algorithm identified patients with evidence of TRD, defined as initiation of a new
antidepressant therapy after 2 different antidepressant trials of adequate dose and duration
during the most recent major depressive episode. Patients receiving treatment on/after …
PMH30 Characteristics of Real-world Commercially Insured Patients with Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional …
Methods Adults with a Major Depressive Disorder diagnosis were selected from the
MarketScan® Databases (01/2010-07/2020). A claims-based algorithm identified TRD as
the initiation of a new antidepressant therapy after 2 different lines of adequate dose and
duration during the most recent major depressive episode. Patients with observed evidence
of TRD receiving treatment on/after 03/05/2019 (esketamine approval date) were then
classified in the esketamine cohort if they initiated esketamine (index date), or conventional …
MarketScan® Databases (01/2010-07/2020). A claims-based algorithm identified TRD as
the initiation of a new antidepressant therapy after 2 different lines of adequate dose and
duration during the most recent major depressive episode. Patients with observed evidence
of TRD receiving treatment on/after 03/05/2019 (esketamine approval date) were then
classified in the esketamine cohort if they initiated esketamine (index date), or conventional …
以上显示的是最相近的搜索结果。 查看全部搜索结果